Pharma Mar S.A (PHM) | Stock Overview & Key Data
Pharma Mar S.A Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: €323.28 on October 2, 2000
Explore how other Spanish stocks compare to their 52-week ranges: View ES Market 52-Week Insights
Key Statistics
Financial Highlights
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Dividend Information
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Pharma Mar S.A
PHM
|
1.68B Large-cap | -2.77% | 9.23% | 17.43% | 27.39% | 23.89% | 30.10% | 151.19% | -0.37% | 186.82% | 180.20% | 30.59% |
| 220.00M Mid-cap | -3.13% | 0.72% | -12.81% | -12.81% | -13.35% | 2.95% | 31.60% | -21.41% | -5.42% | -21.41% | -21.41% | |
|
Atrys Health S.A
ATRY
|
222.81M Mid-cap | -3.65% | 7.41% | -3.65% | -14.20% | -0.68% | 1.75% | -42.91% | -69.15% | 81.25% | 81.25% | 81.25% |
| 144.69M Small-cap | 11.05% | 29.80% | 115.38% | 206.25% | 134.73% | 512.50% | 497.56% | 595.04% | 595.04% | 595.04% | 595.04% | |
| 19.30M Small-cap | 8.33% | 13.04% | 30.00% | -27.78% | 30.00% | -16.13% | -21.21% | -70.79% | -91.88% | -88.50% | -88.50% | |
|
Grifols, S.A
GRF
|
6.09B Large-cap | -7.25% | 1.24% | -18.49% | -20.87% | -20.02% | 5.17% | -3.97% | -60.31% | -52.89% | 33.98% | 244.23% |
Ownership & Short Interest
Calculate Your Pharma Mar S.A Investment Returns
Long-Term Investment Performance Analysis
Pharma Mar S.A stock price in Jul 2016 was €27.12, A €1,000.00 lump sum investment in Pharma Mar S.A made 9 years ago would be worth approximately €3,490.04 today, representing a outstanding return of 249.00%. This translates to an annualized return (CAGR) of 13.65%.
9 Years 9 Months Investment Scenario (Jul 2016 - Apr 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is PHM's 52-week high and low?
- In the last 52 weeks, Pharma Mar S.A reached a high of €102.40 (on October 3, 2025) and a low of €70.10 (on November 5, 2025).
- What is the market cap and P/E ratio for PHM?
- Curious about Pharma Mar S.A's size and valuation? Its market capitalization stands at 1.68B. When it comes to valuation, the P/E ratio (trailing twelve months) is 21.87, and the forward P/E (looking ahead) is 13.13.
- Does PHM pay dividends? If so, what's the yield?
- Yes, Pharma Mar S.A is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.86%, and the company has paid an average of €0.88 per share annually over the past 3 years.
- Who are Pharma Mar S.A's main competitors or similar companies to consider before investing?
When looking at Pharma Mar S.A, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Oryzon Genomics S.A
ORY220.00M Healthcare Biotechnology 2.95% 31.60% Atrys Health S.A
ATRY222.81M Healthcare Biotechnology 1.75% -42.91% Vytrus Biotech S.A
VYT144.69M Healthcare Biotechnology 512.50% 497.56% Biotechnology Assets
BST19.30M Healthcare Biotechnology -16.13% -21.21% Grifols, S.A
GRF6.09B Healthcare Drug Manufacturers - General 5.17% -3.97% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Pharma Mar S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Pharma Mar S.A's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 32.59%, the Debt to Equity ratio from the most recent quarter is 19.62, and its Gross Profit Margin stands at 94.17%.
- What is the recent revenue and earnings growth for PHM?
- Looking at Pharma Mar S.A's growth, its revenue over the trailing twelve months (TTM) was €221M. Compared to the same quarter last year (YoY), quarterly revenue grew by 87.10%, and quarterly earnings saw a YoY growth of 219.30%.
- How much of PHM stock is held by insiders and institutions?
- Wondering who owns Pharma Mar S.A stock? Company insiders (like executives and directors) hold about 24.43% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 8.34%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.